Today, we are thrilled to celebrate a monumental milestone in the world of cancer treatment. We extend our heartfelt congratulations to our neighbor at Mt Eden Research Park Reflexion Medical and the Stanford Radiation Oncology teams for their collaborative dedication and pioneering approach in integrating groundbreaking technology for cancer care.
A New Chapter in Cancer Treatment
Six months ago, Reflexion Medical announced a significant achievement: the FDA approval of SCINTIX™ biology-guided radiotherapy. Today, we are overjoyed to announce that Reflexion has reached another significant milestone – the treatment of their first patient using this revolutionary technology.
SCINTIX: A Game Changer in Radiotherapy
SCINTIX is the world’s first and only radiotherapy that allows each cancer’s unique biology to autonomously determine where and how much radiation to deliver, second-by-second, during actual treatment delivery. This technology transforms cancer cells into real-time biological beacons that guide external-beam radiotherapy delivery to multiple tumors.
As Dr. Terence Williams, Chair of City of Hope’s Department of Radiation Oncology, eloquently stated, “SCINTIX ushers in a new era of external-beam radiotherapy by harnessing data produced from the biologic process of cancer cells, which until now has been untapped.”
A Collaborative Triumph
This milestone is not just a triumph for Reflexion Medical, but it is also a testament to the collaborative spirit and dedication of the Stanford Radiation Oncology teams. Their commitment to integrating new technology into cancer care is helping to bring this innovative treatment to patients, especially those with stage 4 disease, where treatment options often remain very limited.
A Visionary Approach
Reflexion’s CEO and President, Todd Powell, emphasized the novel nature of SCINTIX therapy and the challenges it presented, stating, “From its inception, the novel nature of SCINTIX therapy demanded that we fundamentally rethink how to design a machine capable of delivering cancer treatment to patients that were not considered candidates for radiotherapy because of the extent of their disease.”
A Decade of Dedication
Sam Mazin, Ph.D., Founder and CTO of Reflexion, acknowledged the long journey and the many talented people who contributed over the years to bring SCINTIX therapy to the clinic. “Autonomous radiotherapy was just a concept over a decade ago, but now for the first time in the history of cancer treatment, the individual biology of the cancer itself guides its own destruction,” he said.
Looking to the Future
With the FDA clearance for SCINTIX therapy to treat patients with lung and bone tumors, whether primary or metastatic, Reflexion is poised to change the lives of approximately 430,000 patients who develop these tumors annually.
Congratulations, Reflexion & Stanford Radiation Oncology Teams!
On behalf of all of us at Bonneville Labs, we extend our warmest congratulations to Reflexion Medical and the Stanford Radiation Oncology teams for their incredible work. Your dedication, innovation, and collaboration are not only advancing the field of oncology but are also offering new hope to patients and their families around the world.
Here’s to a future where cancer treatment is more precise, more effective, and more accessible than ever before. #CancerCareRevolution
